Skip to Content
Merck
  • Evidence for altered synthesis of type II collagen in patients with osteoarthritis.

Evidence for altered synthesis of type II collagen in patients with osteoarthritis.

The Journal of clinical investigation (1998-12-17)
F Nelson, L Dahlberg, S Laverty, A Reiner, I Pidoux, M Ionescu, G L Fraser, E Brooks, M Tanzer, L C Rosenberg, P Dieppe, A Robin Poole
ABSTRACT

There is evidence to suggest that the synthesis of type II collagen is increased in osteoarthritis (OA). Using an immunoassay, we show that the content of the C-propeptide of type II procollagen (CPII), released extracellularly from the newly synthesized molecule, is directly related to the synthesis of this molecule in healthy and osteoarthritic articular cartilages. In OA cartilage, CPII content is often markedly elevated (mean 7.6-fold), particularly in the mid and deep zones, reaching 29.6% of the content in newborn. Synthesis is also directly related to total collagen II content in OA, suggesting its importance in maintaining collagen content and cartilage structure. The release of CPII from cartilage is correlated directly with cartilage content. However, the increase in CPII in OA cartilage is not reflected in serum, where a significant reduction is observed. Together these studies provide evidence for alterations in procollagen II synthesis in vivo in patients with OA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Collagen Type I−FITC Conjugate from bovine skin, ~1 mg/mL, solution